• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.

作者信息

Liang J-H, Wang L, Peter Gale R, Wu W, Xia Y, Fan L, Li J-Y, Xu W

机构信息

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.

Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.

出版信息

Blood Cancer J. 2017 Sep 15;7(9):e608. doi: 10.1038/bcj.2017.88.

DOI:10.1038/bcj.2017.88
PMID:29016569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5637107/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6c1/5637107/d37687226149/bcj201788f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6c1/5637107/d37687226149/bcj201788f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6c1/5637107/d37687226149/bcj201788f1.jpg

相似文献

1
Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.聚乙二醇天冬酰胺酶、依托泊苷、甲氨蝶呤和地塞米松治疗新诊断晚期结外自然杀伤/T细胞淋巴瘤的疗效及全血EBV-DNA预后分析
Blood Cancer J. 2017 Sep 15;7(9):e608. doi: 10.1038/bcj.2017.88.
2
A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.一项新诊断的 IE 期至 IIE 期结外 NK/T 细胞淋巴瘤，鼻型患者接受甲氨蝶呤、依托泊苷、地塞米松和培门冬酶与放疗联合治疗的 II 期研究
EBioMedicine. 2017 Nov;25:41-49. doi: 10.1016/j.ebiom.2017.10.011. Epub 2017 Oct 12.
3
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.甲氨蝶呤、依托泊苷、地塞米松和聚乙二醇天冬酰胺酶化疗用于新诊断、复发或难治性鼻型结外自然杀伤/T细胞淋巴瘤的2期研究：中国西北多中心试验
Hematol Oncol. 2017 Dec;35(4):619-629. doi: 10.1002/hon.2325. Epub 2016 Oct 10.
4
High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.大剂量甲氨蝶呤、依托泊苷、地塞米松和聚乙二醇天冬酰胺酶（MEDA）联合化疗对晚期及复发/难治性结外自然杀伤/T细胞淋巴瘤有效：一项回顾性研究
Int J Hematol. 2015 Aug;102(2):181-7. doi: 10.1007/s12185-015-1809-x. Epub 2015 May 22.
5
Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.吉西他滨、顺铂、地塞米松、甲氨蝶呤和培门冬酶（GDP-ML）联合方案治疗初诊结外鼻型自然杀伤/T 细胞淋巴瘤患者的单臂、单中心、前瞻性 2 期研究。
Ann Hematol. 2020 Dec;99(12):2801-2809. doi: 10.1007/s00277-020-04036-z. Epub 2020 May 13.
6
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.吉西他滨、聚乙二醇天冬酰胺酶、顺铂和地塞米松（DDGP）联合化疗治疗复发/难治性结外NK/T细胞淋巴瘤的疗效：一项对17例患者的回顾性研究
Ann Hematol. 2014 Nov;93(11):1889-94. doi: 10.1007/s00277-014-2136-7. Epub 2014 Jun 13.
7
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.治疗前 EBV-DNA 拷贝数可预测结外 NK/T 细胞淋巴瘤，鼻型患者对 SMILE 化疗的反应和毒性。
Clin Cancer Res. 2012 Aug 1;18(15):4183-90. doi: 10.1158/1078-0432.CCR-12-1064. Epub 2012 Jun 6.
8
Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.培门冬酶治疗鼻型结外自然杀伤/T细胞淋巴瘤的疗效：来自中国的一例病例报告
J Cancer Res Ther. 2015 Jul-Sep;11(3):665. doi: 10.4103/0973-1482.140750.
9
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.地塞米松、甲氨蝶呤、异环磷酰胺、L-天冬酰胺酶和依托泊苷（SMILE）化疗方案用于晚期、复发或难治性结外自然杀伤（NK）/T细胞淋巴瘤和白血病的I期研究
Cancer Sci. 2008 May;99(5):1016-20. doi: 10.1111/j.1349-7006.2008.00768.x. Epub 2008 Feb 19.
10
Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.采用SMILE方案进行诱导治疗并联合自体干细胞移植对新诊断的IV期结外自然杀伤/T细胞淋巴瘤患者进行巩固治疗。
Ann Hematol. 2015 Jan;94(1):71-8. doi: 10.1007/s00277-014-2171-4. Epub 2014 Aug 2.

引用本文的文献

1
Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States.自然杀伤/T细胞淋巴瘤的发病率、预后因素及治疗对生存的影响：美国基于人群的研究
JMIR Form Res. 2025 May 15;9:e70129. doi: 10.2196/70129.
2
[Efficacy and safety of PEMD regimen in newly diagnosed early-stage non-upper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma].PEMD方案治疗新诊断的早期非上呼吸道消化道或晚期结外自然杀伤/T细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):147-151. doi: 10.3760/cma.j.cn121090-20241120-00463.
3

本文引用的文献

1
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.非蒽环类药物治疗后自然杀伤细胞淋巴瘤的预后指数：一项多中心回顾性分析。
Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.
2
Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.回顾性研究改良 SMILE 化疗治疗晚期、复发或难治性结外鼻型自然杀伤（NK）/T 细胞淋巴瘤。
Med Oncol. 2013 Dec;30(4):720. doi: 10.1007/s12032-013-0720-7. Epub 2013 Sep 24.
3
Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas.
治疗前和治疗后血浆中爱泼斯坦-巴尔病毒DNA在外周T细胞淋巴瘤中的预后影响
Ann Med. 2025 Dec;57(1):2478315. doi: 10.1080/07853890.2025.2478315. Epub 2025 Mar 20.
4
Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data.克服晚期或复发难治性结外NK/T细胞淋巴瘤的挑战：个体患者数据的荟萃分析
Front Oncol. 2024 Jul 31;14:1362367. doi: 10.3389/fonc.2024.1362367. eCollection 2024.
5
Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV DLBCL-NOS: a Chinese cohort study.治疗过程中循环 EBV-DNA 载量的动态变化对 EBV DLBCL-NOS 具有预后价值：一项中国队列研究。
Ann Hematol. 2023 Sep;102(9):2471-2481. doi: 10.1007/s00277-023-05260-z. Epub 2023 May 10.
6
The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.全血 Epstein-Barr 病毒 DNA 在淋巴瘤相关噬血细胞性淋巴组织细胞增生症中的临床意义和预后作用。
J Clin Immunol. 2023 Aug;43(6):1302-1310. doi: 10.1007/s10875-023-01493-9. Epub 2023 Apr 24.
7
Treatment of extranodal NK/T-cell lymphoma: From past to future.结外 NK/T 细胞淋巴瘤的治疗：从过去到未来。
Front Immunol. 2023 Feb 7;14:1088685. doi: 10.3389/fimmu.2023.1088685. eCollection 2023.
8
NK-/T-cell lymphomas.NK/T 细胞淋巴瘤。
Leukemia. 2021 Sep;35(9):2460-2468. doi: 10.1038/s41375-021-01313-2. Epub 2021 Jun 11.
9
Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab.对包括派姆单抗在内的多种治疗均耐药的同时性眼内和皮肤结外NK/T细胞淋巴瘤
Clin Case Rep. 2021 May 19;9(5):e04194. doi: 10.1002/ccr3.4194. eCollection 2021 May.
10
[Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].晚期结外NK/T细胞淋巴瘤的临床特征及预后分析
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):462-468. doi: 10.3760/cma.j.issn.0253-2727.2020.06.005.
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
SMILE 方案治疗自然杀伤/T 细胞淋巴瘤的疗效和安全性：亚洲淋巴瘤研究组的分析。
Blood. 2012 Oct 11;120(15):2973-80. doi: 10.1182/blood-2012-05-431460. Epub 2012 Aug 23.
4
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.治疗前 EBV-DNA 拷贝数可预测结外 NK/T 细胞淋巴瘤，鼻型患者对 SMILE 化疗的反应和毒性。
Clin Cancer Res. 2012 Aug 1;18(15):4183-90. doi: 10.1158/1078-0432.CCR-12-1064. Epub 2012 Jun 6.
5
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.SMILE 化疗治疗初诊 IV 期、复发或难治性结外鼻型自然杀伤（NK）/T 细胞淋巴瘤的 II 期研究：NK 细胞肿瘤研究组研究。
J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.
6
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.同步放疗与每周顺铂化疗后行VIPD化疗治疗新诊断的IE期至IIE期鼻型结外NK/T细胞淋巴瘤的II期试验：淋巴瘤生存改善联盟研究
J Clin Oncol. 2009 Dec 10;27(35):6027-32. doi: 10.1200/JCO.2009.23.8592. Epub 2009 Nov 2.
7
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.成熟自然杀伤（NK）细胞肿瘤的预后因素：侵袭性 NK 细胞白血病和结外 NK/T 细胞淋巴瘤，鼻型。
Ann Oncol. 2010 May;21(5):1032-40. doi: 10.1093/annonc/mdp418. Epub 2009 Oct 22.
8
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.全血中爱泼斯坦-巴尔病毒DNA载量作为诊断和预后替代指标：结外自然杀伤/T细胞淋巴瘤
Leuk Lymphoma. 2009 May;50(5):757-63. doi: 10.1080/10428190902803669.
9
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.鼻型与鼻外型自然杀伤/T细胞淋巴瘤的临床差异：一项来自国际外周T细胞淋巴瘤项目的136例病例研究。
Blood. 2009 Apr 23;113(17):3931-7. doi: 10.1182/blood-2008-10-185256. Epub 2008 Nov 24.
10
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.地塞米松、甲氨蝶呤、异环磷酰胺、L-天冬酰胺酶和依托泊苷（SMILE）化疗方案用于晚期、复发或难治性结外自然杀伤（NK）/T细胞淋巴瘤和白血病的I期研究
Cancer Sci. 2008 May;99(5):1016-20. doi: 10.1111/j.1349-7006.2008.00768.x. Epub 2008 Feb 19.